重组MIP与CPAF疫苗对绵羊地方性流产的保护与免疫应答评价
本研究将50只C. abortus血清阴性母羊随机分为5组,分别接种MBP-MIP、CPAF、MIP/CPAF联合、Tris缓冲液(阴性对照)或Enzovax(阳性对照),免疫后5个月配种,妊娠第90天攻毒。Enzovax保护率100%,MIP/CPAF联合疫苗使67%母羊产下活羔,疫苗效力50%,单用MIP或CPAF未提供保护。
要点
- MIP/CPAF联合疫苗使67%母羊产活羔,疫苗效力50%,单用无效。
- Enzovax阳性对照无流产发生,保护率100%。
- 流产母羊攻毒后35天IFNγ和IL-10及产后24小时抗体水平显著更高。
核心结论
- MIP/CPAF联合疫苗对C. abortus攻毒提供部分保护,疫苗效力50%,单用MIP或CPAF无保护作用。
研究设计与样本
- 50只C. abortus血清阴性母羊随机分为5组,每组10只,分别接种100 µg MBP-MIP、100 µg CPAF、50 µg MBP-MIP加50 µg CPAF、Tris缓冲液或Enzovax。
- 首免后3周加强免疫,免疫后5个月配种,妊娠第90天攻毒,攻毒后四个时间点采血检测免疫指标,并用qPCR检测C. abortus载量。
主要发现
- Enzovax组100%有效,无流产发生;MIP/CPAF联合疫苗组67%母羊产下至少一只活羔,疫苗效力50%。
- 单用MIP或CPAF未提供保护。
- Enzovax和MIP/CPAF联合疫苗组母羊妊娠期更长,羔羊出生体重高于阴性对照组。
- 流产母羊C. abortus排菌量高于产活羔母羊,所有免疫组排菌量低于阴性对照组,Enzovax组排菌量显著更少。
- 流产母羊攻毒后第35天IFNγ和IL-10水平及产后24小时抗衣原体抗体水平显著高于产活羔母羊。
临床怎么用
- MIP/CPAF联合疫苗可考虑作为绵羊地方性流产的候选疫苗,但保护效力有限,需进一步优化。
- Enzovax仍为标准阳性对照疫苗,保护效果明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
MIP and CPAF from Chlamydia have been shown to be effective in inducing immune responses important in clearing chlamydial infections. This study evaluates the protection conferred by MIP and CPAF as novel vaccines in pregnant C. abortus challenged ewes. Fifty C. abortus sero-negative sheep were randomly allocated into 5 groups of 10 according to the treatment they were to receive (1) 100 µg of MBP-MIP (2) 100 µg CPAF (3) 50 µg MBP-MIP and 50 µg CPAF (4) Tris-buffer (negative control) (5) Enzovax (positive control). Booster inoculations were administered 3 weeks after primary inoculations. Blood samples were taken pre-vaccination and weekly for 5 weeks. Five months after vaccination the ewes were mated. Pregnant ewes were then challenged on day 90 of gestation. Blood samples taken at four time-points post challenge were analysed for IFNγ levels, TNFα and IL-10 expression and anti-chlamydial antibody levels. Vaginal swabs, placental and foetal tissue and bacterial shedding were analysed using qPCR to quantify levels of C. abortus. Enzovax was 100% effective with no abortions occurring. The MIP/CPAF combined vaccine offered the greatest protection of the novel vaccines with 67% of ewes giving birth to one or more live lambs equating to a 50% vaccine efficacy rate. MIP and CPAF administered singly did not confer protection. Enzovax and MIP/CPAF vaccinated ewes had longer gestations and lambs with higher birth weights than negative control ewes. Aborting ewes shed higher numbers of C. abortus than ewes that had live lambs, all vaccinated ewes demonstrated lower levels of bacterial shedding than negative control ewes with Enzovax ewes shedding significantly fewer bacteria. Ewes that went on to abort had significantly higher levels of IFNγ and IL-10 at day 35 post challenge and significantly higher levels of anti-chlamydial antibodies at 24 h post lambing compared to ewes that had live lambs.
引用
- O'Neill LM, Keane OM, Ross PJ, et al. Evaluation of protective and immune responses following vaccination with recombinant MIP and CPAF from Chlamydia abortus as novel vaccines for enzootic abortion of ewes. Vaccine. 2019. PMID: 31375438. doi:10.1016/j.vaccine.2019.06.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。